Hofstetter Gerda, Grech Christina, Pils Dietmar, Pammer Johannes, Neudert Barbara, Pötsch Nina, Baltzer Pascal, Traub-Weidinger Tatjana, Seebacher Veronika, Aust Stefanie
Department of Pathology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC) Vienna, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
J Pers Med. 2022 Mar 31;12(4):551. doi: 10.3390/jpm12040551.
Prostate-specific membrane antigen (PSMA) is present in the tumor-associated neovasculature of many cancer types. Current data in ovarian cancer are limited and controversial; thus, the aim of this study was to investigate PSMA expression in a larger and homogenous patient cohort. This might lead to further studies investigating the use of imaging and therapeutic modalities targeting PSMA. Eighty patients with advanced stage high-grade serous ovarian cancers were included. Using immunohistochemistry, PSMA and CD31, a marker for endothelial cells, were examined in whole tissue sections. Percentage and intensity of PSMA expression were determined in the neovasculature. Expression levels were correlated with clinicopathological parameters and survival. Low (≤10%), medium (20-80%), and high (≥90%) PSMA expression was found in 14, 46, and 20 ovarian cancer samples, respectively. PSMA expression was confined to tumor-associated neovasculature and significantly correlated with progression-free (HR 2.24, 95% CI 1.32-3.82, = 0.003) and overall survival (HR 2.73, 95% CI 1.41-5.29, = 0.003) in multivariate models, considering age, FIGO stage, and residual disease. This is the first study showing a clinical relevance for PSMA in patients with ovarian cancer. PSMA was detected in the vast majority of cancer samples and showed an impact on survival.
前列腺特异性膜抗原（PSMA）存在于多种癌症类型的肿瘤相关新生血管中。目前关于卵巢癌的数据有限且存在争议；因此，本研究的目的是在更大且同质的患者队列中研究PSMA的表达情况。这可能会促使进一步的研究来探究针对PSMA的成像和治疗方式的应用。纳入了80例晚期高级别浆液性卵巢癌患者。使用免疫组织化学方法，在全组织切片中检测PSMA和内皮细胞标志物CD31。在新生血管中确定PSMA表达的百分比和强度。将表达水平与临床病理参数及生存率进行关联分析。在14例、46例和20例卵巢癌样本中分别发现低（≤10%）、中（20 - 80%）和高（≥90%）水平的PSMA表达。PSMA表达局限于肿瘤相关新生血管，在多变量模型中，考虑年龄、国际妇产科联盟（FIGO）分期和残留病灶时，PSMA表达与无进展生存期（HR 2.24，95% CI 1.32 - 3.82，P = 0.003）和总生存期（HR 2.73，95% CI 1.41 - 5.29，P = 0.003）显著相关。这是第一项显示PSMA在卵巢癌患者中具有临床相关性的研究。在绝大多数癌症样本中检测到了PSMA，并且其对生存率有影响。
